Mode
Home
Research
Clinical Trials Drug Pipeline Weekly Digests
Reference
Conditions Medications
Community
Questions
Text Size
Log in / Sign up
Home › Conditions › sarcoma

Sarcoma

Part of Epithelioid Sarcoma

1 published article · Updated continuously

Clinical Trial Landscape

Clinical Trials for sarcoma

80 trials tracked for sarcoma: 5 in phase 3 or 4 and 2 with published results. The most-cited published study has 258 citations.

80Trials tracked
5Phase 3 & 4
0Recruiting
2With published results
Phase distribution
Phase 3 5 Phase 2 55 Phase 1 7 Other / NA 13
  1. Phase 3 Sodium Thiosulfate in Preventing Hearing Loss in Young Patients Receiving Cisplatin for Newly Diagnosed Germ Cell Tumor, Hepatoblastoma, Medulloblastoma, Neuroblastoma, Osteosarcoma, or Other Malignancy Completed · 258 cited
  2. Phase 3 Combination Chemotherapy and Radiation Therapy in Treating Patients With Newly Diagnosed Rhabdomyosarcoma Completed · 176 cited
  3. Phase 3 High-Dose Combination Chemotherapy and Radiation Therapy in Treating Patients With Newly Diagnosed Metastatic Rhabdomyosarcoma or Ectomesenchymoma Completed
  4. Phase 3 An Efficacy and Safety Study of Trabectedin Versus Doxorubicin-Based Chemotherapy in Participants With Translocation-Related Sarcomas (TRS) Completed
  5. Phase 3 Glutamic Acid in Reducing Nerve Damage Caused by Vincristine in Young Patients With Cancer Completed
  6. Phase 2 A Study of Tremelimumab and IV Durvalumab Plus Poly-ICLC in Subjects With Biopsy-accessible Cancers Completed
Show 44 more trials
  1. Phase 2 Glutamine in Treating Neuropathy Caused by Vincristine in Young Patients With Lymphoma, Leukemia, or Solid Tumors Completed
  2. Phase 2 Evaluate PKs and Efficacy Assessment of Palifermin in Patients With Sarcoma Completed
  3. Phase 2 Pembrolizumab and Doxorubicin Hydrochloride in Treating Patients With Sarcoma That is Metastatic or Cannot Be Removed by Surgery Completed
  4. Phase 2 Imatinib Mesylate in Treating Patients With HIV-Related Kaposi's Sarcoma Completed
  5. Phase 2 A Phase II Study of Eribulin and Pembrolizumab in Soft Tissue Sarcomas Completed
  6. Phase 2 Stem Cell Transplantation in Patients With High-Risk and Recurrent Pediatric Sarcomas Completed
  7. Phase 2 PD0332991 (Palbociclib) in Patients With Advanced or Metastatic Liposarcoma Completed
  8. Phase 2 Fondaparinux in Preventing Blood Clots in Patients Undergoing Surgery for Gynecologic Cancer Completed
  9. Phase 2 Samarium Sm 153 and Stem Cell Transplant Followed By Radiation Therapy Patients With Osteosarcoma Completed
  10. Phase 2 Cyclophosphamide, Topotecan, and Bevacizumab (CTB) in Patients With Relapsed/Refractory Ewing's Sarcoma and Neuroblastoma Completed
  11. Phase 2 Vatalanib in Treating Patients With Recurrent or Progressive Meningioma Completed
  12. Phase 2 A Proof-of-concept Study to Assess the Ability of [18F]AH-111585 PET Imaging to Detect Tumours and Angiogenesis Completed
  13. Phase 2 Pilot Study of Hyperthermic Peritoneal Perfusion (HIPEC) for Adolescent and Young Adults With Desmoplastic Small Round Cell Tumor Completed
  14. Phase 2 Dacarbazine for Metastatic Soft Tissue and Bone Sarcoma Completed
  15. Phase 2 Gemcitabine and Docetaxel in Treating Patients With Recurrent Osteosarcoma (Closed to Accrual as of 12/21/06) or Ewing's Sarcoma or Unresectable or Locally Recurrent Chondrosarcoma Completed
  16. Phase 2 Arsenic Trioxide in Treating Patients With Advanced Neuroblastoma or Other Childhood Solid Tumors Completed
  17. Phase 2 Vinblastine, Celecoxib, and Combination Chemotherapy in Treating Patients With Newly-Diagnosed Metastatic Ewing's Sarcoma Family of Tumors Completed
  18. Phase 2 Trivalent Ganglioside Vaccine With Immunological Adjuvant or Immunological Adjuvant Alone in Metastatic Sarcoma Patients Who Are Rendered Disease Free Completed
  19. Phase 2 Combination of MK3475 and Metronomic Cyclophosphamide in Patients With Advanced Sarcomas : Multicentre Phase II Trial Completed
  20. Phase 2 Trabectedin in Combination With Olaparib in Advanced Unresectable or Metastatic Sarcoma Completed
  21. Phase 2 S0505 Sorafenib in Treating Patients With Advanced Soft Tissue Sarcomas Completed
  22. Phase 2 Sorafenib and Dacarbazine in Soft Tissue Sarcoma Completed
  23. Phase 2 Gemcitabine With or Without Pazopanib in Treating Patients With Refractory Soft Tissue Sarcoma Completed
  24. Phase 2 A Phase 1/2 Safety Study of Intratumorally Dosed INT230-6 Completed
  25. Phase 2 Study of Vorinostat in Combination With Gemcitabine and Docetaxel in Advanced Sarcoma Completed
  26. Phase 2 Iodine I 131 Monoclonal Antibody 3F8 in Treating Patients With Central Nervous System Cancer or Leptomeningeal Cancer Completed
  27. Phase 2 SARC016: Study of Everolimus With Bevacizumab to Treat Refractory Malignant Peripheral Nerve Sheath Tumors Completed
  28. Phase 2 Inhaled Sargramostim in Treating Patients With First Pulmonary (Lung) Recurrence of Osteosarcoma Completed
  29. Phase 2 Gemcitabine and Docetaxel With Bevacizumab in Selected Sarcoma Subtypes Completed
  30. Phase 2 Reproducibility of 18F Uptake by Solid Tumors Using PET Imaging Following Intravenous Administration of (18F) Injection Completed
  31. Phase 2 Busulfan, Melphalan, and Thiotepa Followed By a Donor Stem Cell Transplant in Treating Patients With High-Risk Ewing's Tumors Completed
  32. Phase 2 Open Label Extension Study of Conatumumab and Ganitumab (AMG 479) Completed
  33. Phase 2 Therapy to Treat Ewing's Sarcoma, Rhabdomyosarcoma or Neuroblastoma Completed
  34. Phase 2 Cytarabine in Treating Young Patients With Recurrent or Refractory Ewing's Sarcoma Completed
  35. Phase 2 Phase I Dose Escalation of Monthly Intravenous Ra-223 Dichloride in Osteosarcoma Completed
  36. Phase 2 Trial of Cetuximab in Patients With Metastatic and/or Locally Advanced Soft Tissue and Bony Sarcomas Completed
  37. Phase 2 A Phase II Trial Comparing Gemcitabine and Pazopanib Versus Gemcitabine and Docetaxel for Patients With Advanced Soft Tissue Sarcoma Completed
  38. Phase 2 Combination Chemotherapy and Peripheral Stem Cell Transplantation in Treating Patients With Sarcoma Completed
  39. Phase 2 PCI-24781 in Combination With Doxorubicin to Treat Sarcoma Completed
  40. Phase 2 Bevacizumab in Treating Patients With Angiosarcoma Completed
  41. Phase 2 S0330 Erlotinib in Treating Patients With Unresectable or Metastatic Malignant Peripheral Nerve Sheath Tumor Completed
  42. Phase 2 Paclitaxel and Carboplatin in Treating Patients With Persistent or Recurrent Stage III or Stage IV Uterine Cancer Completed
  43. Phase 2 Adjuvant Imatinib in High-risk Gastrointestinal Stromal Tumor (GIST) With C-kit Mutation Completed
  44. Phase 2 Image-Guided Radiation Therapy in Treating Patients With Primary Soft Tissue Sarcoma of the Shoulder, Arm, Hip, or Leg Completed

Showing the 50 most-cited and recently-updated of 80 trials. Browse the full registry →

Trial data sourced from ClinicalTrials.gov. Counts describe the research landscape and are not a treatment recommendation. Informational only — not medical advice.

What the trials found Updated — new results For clinicians

Sarcoma: what the trials found

Established evidence for sarcoma treatment includes the use of dactinomycin, which showed a 36% event-free rate at 4 years following study entry; however, concurrent therapy was associated with adverse events in 53.3% to 79.3% of patients 6. Trabectedin demonstrated objective response rates ranging from 5.9% to 27.0% 4.

Pharmacological studies on other agents show that glutamic acid administration resulted in recorded neurotoxicity at various intervals 5. Additionally, the incidence of toxicity related to VI treatment in patients with UGT1A1 genotypes was not significantly different across groups (p=0.99) when administered with Cyclophosphamide 3. Sodium thiosulfate has also been evaluated in established clinical trials for this condition 2.

Recent results — preliminary, needs further review

  • Pembrolizumab is currently being evaluated in a Phase 2 trial 1.
  • Eribulin is under investigation in a Phase 2 trial 8.
  • A combination of MK3475 with Metronomic CP showed no objective response at 6 months, though non-progression rates varied between 0.0% and 40% across study arms; however, no patients remained alive with a best overall response 7.

For the clinician treating this condition

  • Dactinomycin is associated with significant adverse events when used in concurrent therapy (up to 79.3%) but maintains a 36% event-free rate at 4 years 6.
  • Trabectedin shows variable objective response rates ranging from 5.9% to 27.0% 4.
  • Cyclophosphamide treatment and UGT1A1 genotype do not appear to significantly correlate with the incidence of toxicity related to VI treatment (p=0.99) 3.

AI synthesis of 8 cited trials, updated Jun 27, 2026. Informational only — not medical advice; trial data sourced from ClinicalTrials.gov. How we use AI.

HCP Mode — summaries include clinical detail, trial data, and statistical outcomes.
Patient Mode — summaries use plain language, avoiding clinical jargon.
Ultrasound-guided biopsy shows high accuracy for diagnosing suspicious myometrial lesions
OB/GYN & Women's Health Meta-analysis
Ultrasound-guided biopsy shows high accuracy for diagnosing suspicious myometrial lesions Ultrasound-guided biopsy shows high accuracy for suspicious uterine tumors
This meta-analysis of 5 studies found that ultrasound-guided biopsy for suspicious myometrial lesions has high diagnostic accuracy, with poo…
A new review confirms that ultrasound-guided biopsies are a safe, highly accurate way to determine if a uterine growth is cancerous.
Jul 7, 2026

Research across Epithelioid Sarcoma

Related studies from across the Epithelioid Sarcoma family.

Targeted cytokine delivery platforms in canine oncology provide data for human immuno-oncology dose selection
Allergy & Immunology Sys. Review
Targeted cytokine delivery platforms in canine oncology provide data for human immuno-oncology dose selection Cytokine Therapies Show Potential for Treating Canine Cancers
This mini review synthesizes evidence on targeted cytokine delivery platforms, such as IL-12 and IFN-beta, in dogs with various spontaneous …
New research explores how targeted cytokine delivery systems can treat various cancers in dogs and provide data for future human cancer trea…
Frontiers Jul 6, 2026
Extended resection and intensity-modulated radiotherapy managed a rare primary orbit epithelioid sarcoma
Oncology Sys. Review
Extended resection and intensity-modulated radiotherapy managed a rare primary orbit epithelioid sarcoma Treatment approach for a rare orbit tumor in a young man
This case report describes the diagnosis and management of a 25-year-old male with primary epithelioid sarcoma of the left orbit. The patien…
A 25-year-old man with a rare eye tumor showed no signs of cancer spread after surgery and targeted radiation therapy.
Frontiers Jun 27, 2026
Interval-compressed VDC/IE protocol feasibility and outcomes in 27 Ewing's sarcoma patients at a North African center
Oncology Cohort
Interval-compressed VDC/IE protocol feasibility and outcomes in 27 Ewing's sarcoma patients at a North African center Compressed chemotherapy showed mixed results for Ewing's sarcoma patients in a small study.
This retrospective, single-institutional cohort study evaluated an interval-compressed VDC/IE protocol in 27 patients with Ewing's sarcoma t…
A small study found that a compressed chemotherapy regimen for Ewing's sarcoma had high toxicity and low survival rates.
Frontiers Jun 4, 2026
Protocol for a systematic review and network meta-analysis of second-line soft tissue sarcoma treatments
Oncology Meta-analysis
Protocol for a systematic review and network meta-analysis of second-line soft tissue sarcoma treatments Protocol outlines options for second-line soft tissue sarcoma treatments
This is a protocol for a systematic review and network meta-analysis. It will evaluate second-line pharmacological regimens for advanced sof…
A new protocol maps second-line drug choices for advanced soft tissue sarcoma patients previously treated with anthracyclines, noting curren…
medRxiv May 24, 2026
FDA Approves Pomalyst (pomalidomide) for Multiple Myeloma and Kaposi Sarcoma
Oncology FDA Approval
FDA Approves Pomalyst (pomalidomide) for Multiple Myeloma and Kaposi Sarcoma FDA approves new drug Pomalyst for multiple myeloma and Kaposi sarcoma.
The FDA approved Pomalyst (pomalidomide) for multiple myeloma in combination with dexamethasone after at least two prior therapies, and for …
The FDA approved Pomalyst (pomalidomide) for two conditions: multiple myeloma and Kaposi sarcoma. It offers a new option for patients who ha…
FDA May 2, 2026
Post-hoc analysis suggests regional hyperthermia plus chemotherapy may improve survival in extremity soft tissue sarcoma
Oncology RCT
Post-hoc analysis suggests regional hyperthermia plus chemotherapy may improve survival in extremity soft tissue sarcoma Adding heat to chemo may improve survival for soft-tissue sarcoma patients
This post-hoc analysis of a randomized trial examined overall survival in patients with extremity soft tissue sarcoma receiving neoadjuvant …
A post-hoc analysis of a randomized trial suggests adding regional hyperthermia to chemotherapy improved survival for patients with extremit…
May 1, 2026
mGPS associated with survival in advanced soft tissue sarcoma patients receiving trabectedin treatment in retrospective analysis
Oncology Cohort
mGPS associated with survival in advanced soft tissue sarcoma patients receiving trabectedin treatment in retrospective analysis Blood Work May Predict Who Benefits From Sarcoma Drug
This retrospective cohort study evaluated 60 patients with advanced soft tissue sarcoma treated with trabectedin across multiple tertiary on…
A simple blood test score could help doctors predict how long patients live after starting a specific sarcoma treatment.
Frontiers Apr 23, 2026
Retrospective cohort study assesses delta-NLR and baseline NLR for prognosis in soft tissue sarcoma
Oncology Cohort
Retrospective cohort study assesses delta-NLR and baseline NLR for prognosis in soft tissue sarcoma A Simple Blood Test Change Could Predict Survival in Sarcoma
This retrospective cohort study included 231 patients with soft tissue sarcoma.
Watching how a blood marker changes during treatment may give sarcoma patients a clearer picture of their future.
Frontiers Apr 21, 2026
Case report finds West Nile virus encephalitis in immunocompromised child after transfusions
Infectious Disease Cohort
Case report finds West Nile virus encephalitis in immunocompromised child after transfusions Case report links West Nile virus infection to blood transfusions in Saudi Arabia
A case report with cross-sectional donor screening describes a 4-year-old Saudi girl with Ewing's sarcoma who developed WNV encephalitis aft…
A 4-year-old Saudi girl with cancer developed a serious brain infection after receiving blood transfusions, highlighting risks for vulnerabl…
Frontiers Apr 4, 2026
Case report describes diagnostic challenges in bilateral epithelioid sarcoma of the thigh
Oncology Sys. Review
Case report describes diagnostic challenges in bilateral epithelioid sarcoma of the thigh Imaging tests missed rare cancer in woman with thigh tumors, case report shows
A case report and literature review describes a 47-year-old woman with bilateral thigh masses where ultrasonography and MRI failed to provid…
Common scans missed a rare cancer in a woman with thigh tumors, proving that biopsies are vital when imaging results are unclear.
Frontiers Apr 2, 2026